Novogene Sues Pentagon Over Military Designation

The Chinese genetic sequencing firm challenges its placement on the Defense Department's list of Chinese military companies.

Updated on Nov. 4, 2026 in Biotech

Bold flat-color editorial illustration of a row of clear sample tubes beside a steel cargo container, in deep red, cream, and navy. — Novogene sued the Pentagon on Tuesday in federal court in Washington, contesting its placement on a Defense Department list of Chinese firms allegedly aiding Beijing's military. AI Illustration. Upload story photo >

Novogene, a Chinese genetic sequencing firm, sued the Pentagon late Tuesday in U.S. District Court in Washington. The company contests its addition to a Defense Department list of firms allegedly aiding Beijing's military.

Why it matters

The designation prohibits the Defense Department from directly contracting with listed firms, affecting how U.S. military procurement interacts with Chinese companies. A number of other Chinese firms have also sued the Pentagon over similar designations.

The Defense Department's June addition named five companies, Novogene, Alibaba, Baidu, BYD, and NIO, to its Chinese military companies list. The source does not describe the specific evidence used for the designations or any outcome of the lawsuit.

The players

Novogene

Novogene is a Chinese genetic sequencing company that filed suit against the Pentagon over its military designation.

U.S. Department of Defense

The Defense Department maintains the list of Chinese military companies and placed Novogene on it in June.

The details

Novogene filed suit late Tuesday in U.S. District Court in Washington, challenging its inclusion on the list. The designation bars direct Defense Department contracting with the listed firms, and the company was described as allegedly aiding Beijing's military.

June: The Defense Department added Novogene, Alibaba, Baidu, BYD, and NIO to its Chinese military companies list.
Late Tuesday, November 3, 2026: Novogene sued the Pentagon in U.S. District Court in Washington.

Big Picture

Novogene's lawsuit joins a growing set of challenges from Chinese firms contesting their placement on the Defense Department's Chinese military companies list. The designation, which bars direct Pentagon contracting, is the mechanism these companies are now testing in court.

The designation affects whether U.S. defense agencies can contract directly with the listed firms, which shapes procurement options for the Pentagon. Readers following biotech or defense supply chains may see how such listings affect the firms involved.

The takeaway

Designations on the Defense Department's Chinese military companies list are now being challenged in court by the firms they affect. The outcome of these suits may clarify how such listings are applied.